Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan Sells 40,992 Shares

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 40,992 shares of Neuronetics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $3.28, for a total value of $134,453.76. Following the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at $4,209,427.36. This trade represents a 3.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Neuronetics Trading Up 1.0 %

NASDAQ STIM opened at $3.97 on Thursday. Neuronetics, Inc. has a 52 week low of $0.52 and a 52 week high of $5.07. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The stock’s 50-day moving average price is $2.09 and its 200-day moving average price is $1.38.

Institutional Investors Weigh In On Neuronetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its stake in shares of Neuronetics by 64.5% in the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after purchasing an additional 30,837 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in Neuronetics in the 3rd quarter worth $53,000. HighTower Advisors LLC increased its stake in Neuronetics by 55.5% in the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after buying an additional 87,816 shares in the last quarter. David J Yvars Group raised its holdings in Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after acquiring an additional 14,825 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Neuronetics by 10,954.1% in the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after acquiring an additional 54,442 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.